ResMed Inc. 10-K Summary: Fiscal Year Ended June 30, 2010
Business Context and Reporting Period
This report covers the fiscal year ended June 30, 2010. ResMed Inc. is a leading developer, manufacturer, and distributor of medical equipment for treating, diagnosing, and managing sleep-disordered breathing (SDB), primarily obstructive sleep apnea (OSA). The company operates as a single segment, selling products in over 70 countries. Key product lines include airflow generators (CPAP, VPAP, AutoSet), mask systems, and diagnostic devices. In October 2009, the company acquired Laboratoires Narval SA to expand its therapy offerings with mandibular repositioning devices.
Key Financial Metrics
| Metric | Fiscal 2010 | Fiscal 2009 |
|---|---|---|
| Net Revenues | $1,092.4 million | $920.7 million |
| Gross Profit | $655.5 million | $553.8 million |
| Gross Margin | 60.0% | 60.0% |
| Net Income | $190.1 million | $146.4 million |
| Diluted EPS | $2.45 | $1.90 |
| Operating Cash Flow | $188.2 million | $238.9 million |
| Cash and Equivalents | $488.8 million | $415.7 million |
| Total Debt | $121.7 million | $161.7 million |
| Working Capital | $672.7 million | $584.2 million |
Note: All debt is classified as current as it matures within the next fiscal year.
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased 19% year-over-year, driven by a 19% increase in flow generator sales and an 18% increase in mask and accessory sales. Growth was supported by new product launches (S9 AutoSet/Elite, Swift FX, Mirage SoftGel) and favorable foreign currency movements ($11.8 million impact).
- Profitability: Net income rose 30% to $190.1 million. The effective tax rate decreased slightly to 27.1% from 27.4%, aided by the geographic mix of income and Australian R&D tax benefits.
- Debt Reduction: Total debt decreased by approximately $40 million as the company repaid long-term tranches. All remaining debt ($121.7 million) is due within the next 12 months.
- Share Repurchases: The company repurchased 2.52 million shares for $135.8 million during the fiscal year.
Guidance, Outlook, and Risks
Outlook and Strategy: Management expects continued growth driven by increasing awareness of SDB and its link to cardiovascular disease and diabetes. The company plans to maintain R&D spending at approximately 7% of revenue and SG&A at approximately 30% of revenue. A two-for-one stock split was announced in August 2010.
Key Risks and Contingencies:
- Reimbursement Pressure: U.S. healthcare legislation (PPACA) and Medicare competitive bidding programs pose risks of reduced reimbursement rates. Round 1 of competitive bidding resulted in an average 32% reduction for CPAP devices, effective January 2011.
- Regulatory Compliance: The company faces ongoing risks related to FDA regulations, including potential delays in product clearances and the costs of compliance with quality system regulations.
- Foreign Currency: Significant exposure to the Australian dollar and Euro due to manufacturing costs and international sales. Hedging programs are in place but do not eliminate all risk.
- Legal Proceedings: Ongoing litigation includes a dispute with the University of Sydney regarding intellectual property and a German tax audit for years 1996-1998. Management does not expect these to have a material adverse effect.
Investor Verification Checklist
- Debt Maturity: Verify the refinancing strategy for the $121.7 million in debt maturing by June 2011.
- Reimbursement Impact: Monitor the actual impact of the Medicare competitive bidding program (effective Jan 2011) on U.S. sales volumes and pricing.
- Stock Split: Confirm the post-split trading price and share count following the August 2010 two-for-one split.
- Acquisition Integration: Assess the revenue contribution and integration progress of the Laboratoires Narval SA acquisition.
- Foreign Exchange: Track the Australian dollar and Euro exchange rates, as manufacturing costs are heavily denominated in AUD.